- Home
- » Tags
- » Daunorubicin
Top View
- DRUG NAME: Idarubicin
- Pharmacy Policy: Trisenox (Arsenic Trioxide)
- Acute Promyelocytic Leukemia Facts No
- Experimental Chemotherapy-Induced Skin Necrosis in Swine. Mechanistic Studies of Anthracycline Antibiotic Toxicity and Protection with a Radical Dimer Compound
- Vincristine and Daunorubicin Administration in an Adolescent During ECMO
- Daunorubicin and the Heart Such As Hepatic Uptake, Metabolic Conjugation, Secretion, and Br Med J: First Published As 10.1136/Bmj.4.5942.431 on 23 November 1974
- Synthesis and Evaluation of Daunorubicin-Paclitaxel Dimers
- How to Order Chemotherapy at Shands at the University of Florida - Inpatient
- Cytarabine and Daunorubicin (7 Plus 3)
- DA (3+8)–Cytarabine-Daunorubicin In-Patient Regimen
- Effects of Vincristine in Combination with Methotrexate and Other Antitumor Agents in Human Acute Lymphoblastic Leukemia Cells in Culture1
- Combination Effect of Antitumor Agents, Including Doxorubicin
- New Silicon Compounds As Resistance Modifiers Against Multidrug-Resistant Cancer Cells
- Hemodialysis Drug Removal
- Mutagenic and Cytotoxic Activity of Doxorubicin and Daunorubicin Derivatives on Prokaryotic and Eukaryotic Cells N
- Daunorubicin and Cytarabine) Liposome for Injection, for Cardiac Function That Is Less Than Normal
- COMMENTARY Treatment of Acute Promyelocytic Leukemia in Children
- A Randomized Clinical Trial of Daunorubicin and a Combination of Prednisone, Vincristine, 6-Mercaptopurine, and Methotrexate in Adult Acute Nonlymphocytic Leukemia1
- Hydroxycarbamide for Acute Myeloid Leukaemia (AML)
- Gemtuzumab Ozogamicin (Mylotarg) +DA +Cytarabine
- Important Drug Information
- Daunorubicin and Cytarabine (Vyxeos) When It Is Determined to Be Medically Necessary Because the Medical Criteria and Guidelines Shown Below Are Met
- Mylotarg in Combination with DA
- Daunorubicin Metabolism by Human Hematological Components1
- Facile Formation of a Crosslinked Adduct Between DNA And
- Prolonged Molecular Remission After Arsenic Trioxide and All-Trans Retinoic Acid for Acute Promyelocytic Leukemia Relapsed After Allogeneic Stem Cell Transplantation
- Daunorubicin and Ara-C (Cytarabine) – for Acute Myeloid Leukaemia (AML)
- Oral Methotrexate Is As Effective As Intramuscular in Maintenance Therapy of Acute Lymphoblastic Leukaemia
- Proposal for the Inclusion of Arsenic Therapies in the WHO Model List of ESSENTIAL MEDICINES for the Treatment of Acute Promyelocytic Leukemia
- Guideline for Classification of the Acute Emetogenic Potential of Antineoplastic Medication in Pediatric Cancer Patients
- Randomized Trial of Intermediate-Dose Cytarabine In
- Data Sheet Template
- Arsenic Trioxide Replacing Or Reducing Chemotherapy in Consolidation Therapy for Acute Promyelocytic Leukemia (APL2012 Trial)
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
- Adverse Mucocutaneous Reactions Related to Chemothera- Peutic Agents – Part II Reações Tegumentares Adversas Relacionadas Aos Agentes Antineoplásicos – Parte II
- 1 Mtorc1 Inhibition Induces Resistance To
- Daunorubicin Citrate
- An Effective in Vitro Antitumor Response Against Human Pancreatic Carcinoma with Paclitaxel and Daunorubicin by Induction of Both Necrosis and Apoptosis
- Open Full Page
- Cyclosporin a Reverses Vincristine and Daunorubicin Resistance in Acute Lymphatic Leukemia in Vitro
- Novel Homobarringtonie‑Containing Therapy for the Treatment of Patients with Primary Acute Myeloid Leukemia That Are Resistant to Conventional Therapy
- DRUG NAME: Daunorubicin
- Pan-London Haemato-Oncology Clinical Guidelines Acute Leukaemias and Myeloid Neoplasms Part 2: Acute Myeloid Leukaemia
- DRUG NAME: Doxorubicin
- All Therapy Was Stopped
- Hazardous Drug List
- Age-Adapted Induction Treatment of Acute Lymphoblastic Leukemia in the Elderly and Assessment of Maintenance with Interferon Combined with Chemotherapy
- A Review of Omacetaxine: a Chronic Myeloid Leukemia Treatment Resurrected
- Effects of Daunorubicin, Mitomycin C, Azathioprine and Cyclosporin a On
- Medications That Are Considered Hazardous
- For Personal Use. Only Reproduce with Permission from the Lancet. Continued
- University of Illinois Cancer Center Confidential AML-02: Study of the Activity and Safety of the Addition of Omacetaxine To
- Antineoplastic Drugs
- Overcoming Resistance to FLT3 Inhibitors in the Treatment of FLT3-Mutated AML